Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia

Seminars in Hematology

Volumn 51, Issue 3, 2014, Pages 228-234

  Riches, John C ^a   Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CANCER VACCINE; CD40 LIGAND; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; MONOCLONAL ANTIBODY; RITUXIMAB; T LYMPHOCYTE RECEPTOR; VENETOCLAX;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG INDICATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKEMOGENESIS; LYMPHOCYTE TRANSFER; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD40 LIGAND; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84904409976     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.05.006     Document Type: Article

References (49)

1. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
2. Byrd J.C., Furman R.R., Coutre S.E., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
3. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
4. Kotsiou E., Davies J.K. New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2012, 160:133-135.
5. Pizzolo G., Chilosi M., Ambrosetti A., Semenzato G., Fiore-Donati L., Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood 1983, 62:1289-1296.
6. Goolsby C.L., Kuchnio M., Finn W.G., Peterson L. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry 2000, 42:188-195.
7. Van den Hove L.E., Vandenberghe P., Van Gool S.W., et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res 1998, 22:175-184.
8. Riches J.C., Davies J.K., McClanahan F., et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013, 121:1612-1621.
9. Gorgun G., Holderried T.A., Zahrieh D., Neuberg D., Gribben J.G. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005, 115:1797-1805.
10. Ramsay A.G., Johnson A.J., Lee A.M., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008, 118:2427-2437.
11. Ramsay A.G., Evans R., Kiaii S., Svensson L., Hogg N., Gribben J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121:2704-2714.
12. Ramsay A.G., Clear A.J., Fatah R., Gribben J.G. Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide. Blood 2012, 120:1412-1421.
13. Beyer M., Kochanek M., Darabi K., et al. Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
14. Jak M., Mous R., Remmerswaal E.B., et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:788-801.
15. Bagnara D., Kaufman M.S., Calissano C., et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011, 117:5463-5472.
16. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
17. Burger J.A., Quiroga M.P., Hartmann E., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
18. Flinn I.W., Schreeder M.T., Wagner-Johnson N.D., et al. A Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies. Blood 2010, 116. (Abstract 2832).
19. Ponader S., Chen S.S., Buggy J.J., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
20. Dubovsky J.A., Beckwith K.A., Natarajan G., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-2549.
21. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
22. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
23. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
24. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
25. Badoux X.C., Keating M.J., Wen S., et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013, 31:584-591.
26. Chen C.I., Bergsagel P.L., Paul H., et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2010, 29:1175-1181.
27. Idler I., Giannopoulos K., Zenz T., et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2009, 148:948-950.
28. Chanan-Khan A., Miller K.C., Lawrence D., et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011, 117:2127-2135.
29. Aue G., Njuguna N., Tian X., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
30. Dazzi F., D'Andrea E., Biasi G., et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 1995, 75:26-32.
31. Castro J.E., Melo-Cardenas J., Urquiza M., Barajas-Gamboa J.S., Pakbaz R.S., Kipps T.J. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res 2012, 72:2937-2948.
32. Blyth E., Clancy L., Simms R., et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013, 121:3745-3758.
33. Hudecek M., Schmitt T.M., Baskar S., et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010, 116:4532-4541.
34. Fukuda T., Chen L., Endo T., et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 2008, 105:3047-3052.
35. June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009, 9:704-716.
36. Cartellieri M., Bachmann M., Feldmann A., et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010, 2010:956304.
37. Maiti S.N., Huls H., Singh H., et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 2013, 36:112-123.
38. Koehler P., Schmidt P., Hombach A.A., Hallek M., Abken H. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2011, 2012. (595060).
39. Kowolik C.M., Topp M.S., Gonzalez S., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66:10995-11004.
40. Milone M.C., Fish J.D., Carpenito C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009, 17:1453-1464.
41. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
42. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
43. Brentjens R., Yeh R., Bernal Y., Riviere I., Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010, 18:666-668.
44. Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
45. Kochenderfer J.N., Dudley M.E., Carpenter R.O., et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:4129-4139.
46. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
47. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3. 95ra73.
48. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822-1826.
49. Boissel L., Betancur M., Wels W.S., Tuncer H., Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009, 33:1255-1259.